Effects of methylphenidate hydrochloride on the cardiovascular system in vivo and in vitro: A safety pharmacology study

Journal of Pharmacological and Toxicological Methods

Volumn 59, Issue 3, 2009, Pages 128-134

  Wakamatsu, Akihide ^a   Nomura, Shunji ^a   Tate, Yoshiki ^b   Shimizu, Shigekazu ^b   Harada, Yasushi ^a  

^a Janssen Pharmaceutical KK   (Japan)

^b Fuji Biomedix Co Ltd   (Japan)

Author keywords

Action potential duration; Attention deficit hyperactivity disorder (ADHD); Cardiovascular system; IKr; Methylphenidate hydrochloride; QTcF interval

Indexed keywords

METHYLPHENIDATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE MEASUREMENT; BODY SURFACE; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG SAFETY; ELECTROCARDIOGRAM; GUINEA PIG; HEART RATE; HEART REPOLARIZATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; QT INTERVAL; QT PROLONGATION; TELEMETRY;

ACTION POTENTIALS; ADMINISTRATION, ORAL; ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CELL LINE; CENTRAL NERVOUS SYSTEM STIMULANTS; DELAYED RECTIFIER POTASSIUM CHANNELS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; ETHER-A-GO-GO POTASSIUM CHANNELS; GUINEA PIGS; HEART CONDUCTION SYSTEM; HEART RATE; HUMANS; MALE; METHYLPHENIDATE; PAPILLARY MUSCLES; TELEMETRY;

CANIS FAMILIARIS; CAVIA;

EID: 67349236069     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2009.01.003     Document Type: Article

References (46)

1. American Academy of Pediatrics. Clinical practice guideline. Treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics vol. 108 (2001) 1033-1044
2. Anderson M.E., Al-Khatib S.M., Roden D.M., and Califf R.M. Cardiac repolarization: Current knowledge, critical gaps and new approaches to drug development and patient management. American Heart Journal 144 (2002) 769-781
3. Anon. (2002). Application Number: 21-411, Pharmacology Review. Center for Drug Evaluation and Research, August 5, Available from: http://www.fda.gov/cder/foi/nda/2002/21-411_Strattera.htm
4. Anon. The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals (2005, May 12) (S7B), Step 4
5. Ballard J.E., Boileau R.A., Sleator E.K., Massey B.H., and Sprague R.L. Cardiovascular responses of hyperactive children to methylphenidate. JAMA 236 (1976) 2870-2874
6. Brown R.T., and Sexson S.B. Effects of methylphenidate on cardiovascular responses in attention deficit hyperactivity disordered adolescents. Journal of Adolescent Health Care 10 (1989) 179-183
7. Carboni E., and Silvagni A. Experimental investigations on dopamine transmission can provide clues on the mechanism of the therapeutic effect of amphetamine and methylphenidate in ADHD. Neural Plasticity 11 (2004) 77-95
8. Challman T.D., and Lipsky J.J. Methylphenidate: Its pharmacology and uses. Mayo Clinic Proceeding 75 (2000) 711-721
9. De Ponti F., Poluzzi E., and Montanaro N. Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: A call for consensus. European Journal of Clinical Pharmacology 57 (2001) 185-209
10. 99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment. European Journal of Nuclear Medicine 27 (2000) 1518-1524
11. 14C: Studies in man and animals. Journal of Pharmacology and Experimental Therapeutics 191 (1974) 535-547
12. FDA, 1987. Good Laboratory Practice Regulations (21 CFR Part 58) October 5, 1987.
13. Fridericia L.S. Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken. Acta Medica Scandinavica 53 (1920) 469-486
14. Gatley S.J., Pan D., Chen R., Chaturvedi G., and Ding Y.S. Affinities of methylphenidate derivatives for dopamine, norepinephrine and serotonin transporters. Life Science 58 (1996) PL231-PL239
15. Gauvin D.V., Tilley L.P., Smith Jr. F.W.K., and Baird T.J. Electrocardiogram, hemodynamics, and core body temperatures of the normal freely moving laboratory beagle dog by remote radiotelemetry. Journal of Pharmacological and Toxicological Methods 53 (2006) 128-139
16. Greenhill L.L., Pliszka S., Dulcan M.K., Bernet W., Arnold V., Beitchman J., et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. Journal of American Academy of Child and Adolescent Psychiatry 41 (2002) 26S-49S
17. Hayashi S., Kii Y., Tabo M., Fukuda H., Itoh T., Shimosato T., et al. QT PRODACT: A multi-site study of in vitro action potential assays on 21 compounds in isolated guinea-pig papillary muscles. Journal of Pharmacological Sciences 99 (2005) 423-437
18. Hungund B.L., Perel M.J., Hurwic M., Sverd J., and Winsberg B.G. Pharmacokinetics of methylphenidate in hyperkinetic children. British Journal of Clinical Pharmacology 8 (1979) 571-576
19. Ilgenli T.F., Congologlu A., Ozturk C., Turkbay T., Akpinar O., and Kilicaslan F. Acute effect of methylphenidate on QT interval duration and dispersion in children with attention deficit hyperactivity disorder. Advances in Therapy 24 (2007) 182-188
20. Joyce P.R., Nicholls M.G., and Donald R.A. Methylphenidate increases heart rate, blood pressure and plasma epinephrine in normal subjects. Life Science 34 (1984) 1707-1711
21. Kelly R.P., Yeo K.P., Teng C.H., Smith B.P., Lowe S.L., Soon D., et al. Hemodynamic effects of acute administration of atomoxetine and methylphenidate. Journal of Clinical Pharmacology 45 (2005) 851-855
22. Kimko H., Cross J.T., and Abernethy D.R. Pharmacokinetics and clinical effectiveness of methylphenidate. Clinical Pharmacokinetics 37 (1999) 457-470
23. Krause K.-H., Dresel S.H., Krause J., Kung H.F., and Tatsch K. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: Effects of methylphenidate as measured by single photon emission computed tomography. Neuroscience Letters 285 (2000) 107-110
24. Kuczenski R., and Segal D.S. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: Comparison with amphetamine. Journal of Neurochemistry 68 (1997) 2032-2037
25. Kujacic M., Hansson L.O., and Carlsson A. Acute dopaminergic influence on plasma adrenaline levels in the rat. European Journal of Pharmacology 273 (1995) 247-257
26. 3H]β-CIT: A radioligand for dopamine transporters in rat brain tissue. European Journal of Pharmacology 385 (1999) 291-294
27. Meier R., Gross F., and Tripod J. Ritalin, Eine Neuartige Synthetische Verbindung mit Spezifischer Zentralerregender Wirkungskomponente. Klinische Wochenschrift 32 (1954) 445-450
28. Ministry of Health and Welfare (1997). Ordinance of Good Laboratory Practice (Drug GLP), Ordinance No. 21, March 26, 1997.
29. National Institutes of Health Consensus Statement. (1998). Diagnosis and treatment of attention deficit hyperactivity disorder (ADHD). 16(2).
30. Newton J.E., Chapin J.L., and Murphree O.D. Correlations of normality and nervousness with cardiovascular functions in pointer dogs. The Pavlovian Journal of Biological Science 11 (1976) 105-120
31. OECD, 1997. OECD Principles of Good Laboratory Practice (as revised in 1997), ENV/MC/CHEM(98)17, OECD, Paris, 1998. (No.1 in OECD Series on Principles of Good Laboratory Practice and Compliance Monitoring).
32. Redfern W.S., Carlsson L., Davis S., Lynch W.G., MacKenzie I., Palethorpe S., et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation, and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovascular Research 58 (2003) 32-45
33. Stevenson R.D., and Wolraich M.L. Stimulant medication therapy in the treatment of children with attention deficit hyperactivity disorder. Pediatric Clinics of North America 36 (1989) 1183-1197
34. Swanson J., Gupta S., Lam A., Shoulson I., Lerner M., Modi N., et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Archives of General Psychiatry 60 (2003) 204-211
35. Tattersall M.L., Dymond M., Hammond T., and Valentin J.P. Correction of QT values to allow for increases in heart rate in conscious Beagle dogs in toxicology assessment. Journal of Pharmacological and Toxicological Methods 53 (2006) 11-19
36. Taylor E., Sergeant J., Doepfner M., Gunning B., Overmeyer S., Mobius H.J., et al. Clinical guidelines for hyperkinetic disorder. European Child and Adolescent Psychiatry 7 (1998) 184-200
37. Teo S.K., Stirling D.I., Thomas S.D., Evans M.G., and Khetani V.D. A 90-day oral gavage toxicity study of d-methylphenidate and d,l-methylphenidate in beagle dogs. International Journal of Toxicology 22 (2003) 215-226
38. Thai D.L., Yurasits L.N., Rudolph G.R., and Perel J.M. Comparative pharmacokinetics and tissue distribution of the d-enantiomers of para-substituted methylphenidate analogs. Drug Metabolism and Disposition 27 (1999) 645-650
39. Thomas S.H.L. Drugs, QT interval abnormalities and ventricular arrhythmias. Adverse Drug Reactions and Toxicological Reviews 13 (1994) 77-102
40. Viskin S. Long QT syndromes and torsade de pointes. Lancet 354 (1999) 1625-1633
41. Volkow N.D., Wang G.J., Fowler J.S., Monina P.E., Logan J., Gatley S.J., et al. Cardiovascular effects of methylphenidate in humans are associated with increases of dopamine in brain and of epinephrine in plasma. Psychopharmacology 166 (2003) 264-270
42. Vormberge T., Hoffmann M., and Himmel H. Safety pharmacology assessment of drug-induced QT-prolongation in dogs with reduced repolarization reserve. Journal of Pharmacological andToxicological Methods 54 (2006) 130-140
43. 11C]raclopride in the human brain in response to methylphenidate. Journal of Nuclear Medicine 40 (1999) 1285-1291
44. Westfall T.C., and Westfall D.P. Adrenergic agonists and antagonists. In: Brunton L.L., Lazo J.S., and Parker K.L. (Eds). Goodman and Gilman's the pharmacological basis of therapeutics (2006), McGraw-Hill, New York 237-295
45. Wilens T.E., Hammerness P.G., Biederman J., Kwon A., Spencer T.J., Clark S., et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. Journal of Clinical Psychiatry 66 (2005) 253-259
46. Yao J.A., Du X., Lu D., Baker R.L., Daharsh E., and Atterson P. Estimation of potency of HERG channel blockers: Impact of voltage protocol and temperature. Journal of Pharmacological and Toxicological Methods 52 (2005) 146-153